RBC Capital raised the firm’s price target on Argenx (ARGX) to $925 from $860 and keeps an Outperform rating on the shares. While the stock has performed strongly over the last few months, the firm sees upside from here, with Argenx having both commercial execution and a pipeline, the analyst tells investors in a research note. There aren’s many Biotech companies that will likely add about $2B to their top line next year and materially expand margins, the firm added.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx Se: Strategic Focus and Growth Potential in Graves’ Disease Treatment Justifies Buy Rating
- Argenx exit leaves more room for Viridian in TED, says Truist
- argenx Discontinues Phase 3 UplighTED Studies for Thyroid Eye Disease
- Argenx discontinues Phase 3 UplighTED studies following IDMC recommendation
- Argenx’s Efgartigimod Study: A New Horizon in CIDP Treatment